Common questions about Icg (FAQ)
Q: How long after injection does Icg stay visible in the body?
Indocyanine Green (Icg) is removed from the bloodstream very quickly. Official pharmacokinetic data indicates that the dye has a rapid half-life, meaning the amount in the blood reduces by half in about 2.5 to 3 minutes in healthy individuals. This characteristic clearance pattern is noted in its function as a diagnostic agent.
Q: How quickly does Icg leave the body after a procedure?
Icg is cleared from the body solely by the liver and is excreted unchanged into the bile without being chemically changed or broken down. This unique clearance pathway is utilized in procedures for assessing liver function, as the rate at which it disappears from the bloodstream reflects the liver's capacity to process it.
Q: Can Icg interact with blood pressure medications?
Official regulatory documents do not list any formal drug-drug contraindications or interactions specifically involving common blood pressure-lowering medications. However, it is important to inform the healthcare team about all medicines and supplements being taken prior to the procedure.
Q: How does Icg usage change for patients with known severe allergies?
The use of Icg is strictly forbidden in individuals who have a known history of hypersensitivity or severe allergic reaction to the dye itself. Caution is also noted regarding patients with a history of iodide allergy because the product contains sodium iodide. A healthcare provider assesses these risks before administration.
Q: What is the general success rate described in studies when using Icg for imaging?
Studies describe Icg's use as a diagnostic tool, noting that it provides a visual signal in real-time for structures like blood vessels. However, official regulatory documents state that evidence is limited regarding whether this improved visualization definitively links to long-term patient survival or clinical outcomes across all uses.
Q: Is the Icg injection usually painful?
Official labeling notes that injection site reactions are a documented adverse event. Some patient information resources suggest that a patient may experience slight pain, redness, or bruising at the injection site, similar to having blood drawn.
Q: Are there any specific warnings about Icg for people with heart conditions?
Official warnings specify that serious adverse events, including death from anaphylaxis, have been reported following Icg administration, including in patients undergoing certain cardiac procedures. Official warnings state that appropriate equipment must be readily available when Icg is administered, particularly in procedures involving the heart.
Q: What is the maximum amount of Icg that can be administered in one setting?
The total cumulative dose is restricted and should not exceed 2 mg per kilogram (2 mg/kg) of body weight, regardless of the number of injections required during a prolonged procedure.
Q: Is feeling dizzy or nauseous common after an Icg injection?
Nausea, vomiting, and dizziness are listed as documented adverse reactions in official labeling. However, the regulatory documents classify the frequency of these reactions as 'Rare' or 'Not known,' meaning they cannot be reliably estimated from available data.
Q: Are there any food or drink restrictions before receiving Icg?
Official labeling does not specify general food or drink restrictions before Icg administration. However, when Icg is utilized for Hepatic Function Studies (to test liver capacity), the procedure is typically performed when the patient is in a fasting, basal state.
Q: What is the difference between Icg used for imaging and Icg used for function testing?
Icg is officially indicated for two main diagnostic purposes. The first is imaging, where it is used to determine blood flow and tissue perfusion. The second is function testing, where its unique clearance by the liver is utilized for assessing liver function and cardiac output (the heart’s performance).
Q: Where can I find the official regulatory document (like a package insert) for Icg?
Official, government-approved documents like the package insert, or prescribing information, can be found on government websites. In the United States, these are available through resources such as the DailyMed website maintained by the National Institutes of Health (NIH) and the FDA’s Drugs@FDA database.
Q: Is there any risk of contamination or irritation at the injection site?
Icg is supplied as a sterile powder and must be reconstituted using a sterile technique. Regarding patient safety, injection site reactions are listed as documented adverse reactions in the official regulatory safety profile.
Q: Are there generic versions of Icg available?
According to official regulatory records in the United States, there are currently no FDA-approved generic versions of Indocyanine Green available on the market.
Q: What are the long-term effects of having received Icg in the past?
Official regulatory documents state that no studies have been performed to evaluate Icg’s potential for long-term effects, such as carcinogenicity (cancer-causing potential) or mutagenicity. Additionally, clinical studies often have limited follow-up durations after the dye is used.
